Valuation: Becton, Dickinson and Company

Market Cap 45.83B 40.27B 37.59B 34.5B 64.58B 4,390B 66.17B 446B 174B 2,172B 172B 168B 7,510B P/E 2026 *
36.2x
P/E 2027 * 23.6x
Enterprise Value 62.03B 54.5B 50.87B 46.69B 87.4B 5,941B 89.55B 603B 236B 2,940B 233B 228B 10,163B EV / Sales 2026 *
3.23x
EV / Sales 2027 * 3.02x
Free-Float
74.04%
Yield 2026 *
2.36%
Yield 2027 * 2.39%
1 week+8.28%
Current month+10.08%
1 month+6.35%
3 months+14.52%
6 months+8.84%
Current year+10.88%
1 week 133.06
Extreme 133.06
148.18
1 month 130.7
Extreme 130.7
148.18
3 years 111.9
Extreme 111.90117625
208.3
5 years 111.9
Extreme 111.90117625
210.13
10 years 111.9
Extreme 111.90117625
210.13
Manager TitleAgeSince
Chief Executive Officer 53 28/01/2020
Director of Finance/CFO 44 05/12/2025
Compliance Officer - 01/02/2023
Director TitleAgeSince
Director/Board Member 75 24/09/2002
Director/Board Member 71 26/07/2010
Chairman 53 28/04/2021
Change 5-day change 1-year change 3-year change Capi.($)
+0.58%+3.19%+16.07%-28.01% 45.83B
+0.68%+7.39%-15.63%-2.99% 187B
+0.76%+6.90%-5.30%-0.25% 111B
-0.30%+6.00%+9.95%+70.47% 62.18B
+0.34%-6.62%+21.84%+49.32% 48.4B
-1.06%+7.80% - - 34.26B
+0.39%+5.19%-15.90%-39.68% 28.88B
+0.20%-5.85%+33.42%-8.31% 23.72B
+1.95%+11.52%+2.83%+4.11% 22.45B
+4.08%+6.34%-8.01%+5.00% 20.63B
Average +0.57%+1.47%+4.36%+5.52% 59.84B
Weighted average by Cap. +0.03%+3.91%-1.57%+6.82%

Financials

2026 *2027 *
Net sales 19.21B 16.88B 15.76B 14.46B 27.07B 1,840B 27.74B 187B 73.08B 911B 72.14B 70.57B 3,148B 19.72B 17.33B 16.18B 14.85B 27.79B 1,889B 28.48B 192B 75.02B 935B 74.05B 72.44B 3,232B
Net income 1.12B 988M 922M 847M 1.58B 108B 1.62B 10.94B 4.28B 53.31B 4.22B 4.13B 184B 1.45B 1.27B 1.19B 1.09B 2.04B 139B 2.09B 14.1B 5.51B 68.69B 5.44B 5.32B 237B
Net Debt 16.19B 14.23B 13.28B 12.19B 22.82B 1,551B 23.38B 157B 61.59B 768B 60.8B 59.48B 2,653B 13.82B 12.14B 11.33B 10.4B 19.47B 1,323B 19.95B 134B 52.55B 655B 51.87B 50.75B 2,264B
Logo Becton, Dickinson and Company
Becton, Dickinson and Company specializes in the development, manufacturing and marketing of medical and diagnostic equipment and materials. Net sales break down by family of products as follows: - medical management systems (52.4%): medication delivery systems, pharmaceutical systems, advanced patient monitoring systems, etc.; - interventional medical equipment (23.9%): surgical instruments, urological care products, etc.; - diagnostic materials and clinical research and development tools (23.7%): automated systems for blood testing, mycobacteria detection, and molecular biology, medical biology devices, tools for studying genes and culturing cells, instruments for sorting and analyzing cells, monoclonal antibodies, etc. Net sales are distributed geographically as follows: the United States (58.6%), Europe/Middle East/Africa (21.6%), Asia (14.2%) and other (5.6%).
Employees
-
Date Price Change
30/07/26 146.78 +0.58%
28/07/26 €145.94 +4.33%
27/07/26 €139.88 +1.82%
24/07/26 €137.38 +2.13%
23/07/26 €134.52 +0.30%
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
166.34USD
Average target price
180.25USD
Spread / Average Target
+8.36%

Quarterly revenue - Rate of surprise